Pharmacodynamics
From week 12 through week 52, CRP levels in the sarilumab groups were maintained at < 10 mg/L and were lower than that observed in the PBO groups (Additional file Mean changes in IL-6 and sIL-6R levels over time from baseline through week 52 are depicted in Fig. Change from baseline in IL-6 and sIL-6R levels during the 52W treatment period — safety population: 